Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etirinotecan Pegol in Metastatic/Recurrent NSCLC
NCT01773109Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2013
- Primary completion
- Jan 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etirinotecan pegol in non-small cell lung cancer (NSCLC), sponsored by Abramson Cancer Center. Started Jan 2013; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01773109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773109.